← All trials
NCT06950385
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 18, 2025
- Primary completion
- Jul 31, 2030
- Completion date
- Jan 31, 2031
- First posted
- Apr 30, 2025
- Last posted
- Oct 29, 2025
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emtora BiosciencesLead sponsor
- Biodexa PharmaceuticalsCollaborator
- LumaBridgeOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.